Every 10-Q that Lite Strategy, Inc. (LITS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LITS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LITS filings page.
Lite Strategy, Inc. reported a sharp increase in losses as it pivoted from drug development toward a Litecoin-focused treasury strategy for the quarter ended March 31, 2026. The company recorded a net loss of $23.7 million for the quarter and $58.1 million for the nine months, largely driven by a $46.0 million nine‑month loss from changes in the fair value of digital assets and related receivables.
Total assets rose to $57.8 million, dominated by $48.2 million of Litecoin-related digital assets and receivables, while cash and cash equivalents declined to $7.5 million. A $100.0 million PIPE financing in July 2025 funded the acquisition of LTC and new advisory and asset management warrants.
The company also authorized a $25.0 million share repurchase program and bought back about 1.6 million shares for $2.0 million during the nine months. Lite Strategy began writing covered call options on its LTC holdings to generate cash, exposing results to further digital asset price volatility under new fair value accounting.
Lite Strategy, Inc. reported a sharp increase in scale and a major shift in strategy for the quarter ended December 31, 2025. Total assets rose to $82.9 million from $18.3 million in June, driven mainly by $63.97 million of Litecoin holdings and $7.35 million of digital assets receivable tied to covered call option activity.
The company recorded a quarterly net loss of $30.8 million, compared with $2.7 million a year earlier, largely due to a $26.5 million decrease in the fair value of digital assets and related receivable remeasurement. Lite Strategy closed a $100.0 million PIPE in July 2025, issued common stock and pre-funded warrants, and then deployed $100.0 million to purchase Litecoin, adopting a Litecoin Treasury Strategy alongside its legacy oncology pipeline. It also authorized a $25.0 million share repurchase program and began buying back stock, repurchasing 137,541 shares for $0.2 million during the quarter, while ending with $8.8 million in cash and cash equivalents.
Lite Strategy, Inc. (Nasdaq: LITS) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $3.6 million, a narrower loss than the $8.0 million in the prior year period, as operating expenses declined with R&D falling to $10 thousand and G&A to $3.1 million. A $0.6 million loss from change in fair value of digital assets was recognized.
Balance sheet strength shifted to digital assets. Cash and cash equivalents were $10.1 million, and Litecoin holdings were $99.4 million, reflecting 929,548 LTC acquired under the new Litecoin Treasury Strategy following a $100.0 million July 2025 PIPE. Total assets were $113.3 million and stockholders’ equity was $112.3 million.
Capital actions and liquidity. In July, the company issued 23.2 million common shares at $3.42 and pre-funded warrants in the PIPE, and raised an additional $4.6 million net via its ATM. Operating cash use was $4.5 million; $100.0 million was deployed to purchase LTC; financing provided $96.6 million. Subsequent to quarter-end, remaining PIPE pre-funded warrants were exercised and the Board authorized a $25.0 million share repurchase program.